Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression.

Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, Patel NL, Palmieri EM, Weiss JM, Lee JM, Annunziata CM, Rouault TA, Durum SK, McVicar DW.

Nat Commun. 2018 Nov 30;9(1):5099. doi: 10.1038/s41467-018-07505-2.

2.

Identification of an elaborate NK-specific system regulating HLA-C expression.

Li H, Ivarsson MA, Walker-Sperling VE, Subleski J, Johnson JK, Wright PW, Carrington M, Björkström NK, McVicar DW, Anderson SK.

PLoS Genet. 2018 Jan 12;14(1):e1007163. doi: 10.1371/journal.pgen.1007163. eCollection 2018 Jan.

3.

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours.

Scarzello AJ, Jiang Q, Back T, Dang H, Hodge D, Hanson C, Subleski J, Weiss JM, Stauffer JK, Chaisaingmongkol J, Rabibhadana S, Ruchirawat M, Ortaldo J, Wang XW, Norris PS, Ware CF, Wiltrout RH.

Gut. 2016 Oct;65(10):1765-75. doi: 10.1136/gutjnl-2014-308810. Epub 2015 Jul 23.

4.

Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

Subleski JJ, Scarzello AJ, Alvord WG, Jiang Q, Stauffer JK, Kronfli A, Saleh B, Back T, Weiss JM, Wiltrout RH.

J Hepatol. 2015 Nov;63(5):1181-9. doi: 10.1016/j.jhep.2015.06.021. Epub 2015 Jul 2.

5.

Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH.

J Immunol. 2014 Jun 15;192(12):5821-9. doi: 10.4049/jimmunol.1400404. Epub 2014 May 7.

6.

IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice.

Hodge DL, Berthet C, Coppola V, Kastenmüller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, Ortaldo JR, Lin F, Reynolds DA, Sanford ME, Kaldis P, Tessarollo L, Klinman DM, Young HA.

J Autoimmun. 2014 Sep;53:33-45. doi: 10.1016/j.jaut.2014.02.003. Epub 2014 Feb 28.

7.

Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, Hanna N, Alexander HR, Maitra A, Hussain SP.

Int J Cancer. 2013 Feb 15;132(4):785-94. doi: 10.1002/ijc.27736.

8.

Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.

Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.

PLoS One. 2012;7(3):e33303. doi: 10.1371/journal.pone.0033303. Epub 2012 Mar 13.

9.

The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH.

Immunotherapy. 2011 Oct;3(10):1167-84. doi: 10.2217/imt.11.117. Review.

10.

TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.

Subleski JJ, Hall VL, Wolfe TB, Scarzello AJ, Weiss JM, Chan T, Hodge DL, Back TC, Ortaldo JR, Wiltrout RH.

J Immunol. 2011 Jan 15;186(2):838-47. doi: 10.4049/jimmunol.1001735. Epub 2010 Dec 10.

11.

Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.

Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ.

J Immunol. 2010 Jul 1;185(1):174-82. doi: 10.4049/jimmunol.0903548. Epub 2010 Jun 4.

12.

Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood.

Chen X, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, Oppenheim JJ.

Eur J Immunol. 2010 Apr;40(4):1099-106. doi: 10.1002/eji.200940022.

13.

Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.

Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19455-60. doi: 10.1073/pnas.0909474106. Epub 2009 Nov 5.

14.

Editorial: NKT cells: to suppress or not to suppress, that is the question.

Subleski JJ, Ortaldo JR.

J Leukoc Biol. 2009 Oct;86(4):751-2. doi: 10.1189/jlb.0309118. No abstract available.

15.

Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.

Subleski JJ, Wiltrout RH, Weiss JM.

J Autoimmun. 2009 Nov-Dec;33(3-4):275-81. doi: 10.1016/j.jaut.2009.07.010. Epub 2009 Aug 13. Review.

16.

Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.

Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, Bere W, Yang Y, Savan R, Subleski JJ, Yin XM, Loughran TP Jr, Young HA.

Cancer Res. 2009 May 1;69(9):3986-94. doi: 10.1158/0008-5472.CAN-08-3735. Epub 2009 Apr 14.

17.

Nitric oxide is a key component in inflammation-accelerated tumorigenesis.

Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, Hofseth AB, Bernard M, Schwank J, Nguyen G, Mathe E, Djurickovic D, Haines D, Weiss J, Back T, Gruys E, Laubach VE, Wiltrout RH, Harris CC.

Cancer Res. 2008 Sep 1;68(17):7130-6. doi: 10.1158/0008-5472.CAN-08-0410.

18.
19.

Multiprobe ribonuclease protection assay for simultaneous measurement of mRNA expression.

Young HA, Subleski JJ, Krebs SM.

Curr Protoc Immunol. 2003 Aug;Chapter 10:Unit 10.29. doi: 10.1002/0471142735.im1029s54. Review.

PMID:
18432896
20.

Immunotherapy of cancer by IL-12-based cytokine combinations.

Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH.

Expert Opin Biol Ther. 2007 Nov;7(11):1705-21. Review.

21.

Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.

Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH.

Cancer Res. 2006 Nov 15;66(22):11005-12.

22.

The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death.

Hodge DL, Subleski JJ, Reynolds DA, Buschman MD, Schill WB, Burkett MW, Malyguine AM, Young HA.

J Interferon Cytokine Res. 2006 Oct;26(10):706-18.

PMID:
17032165
23.
24.

Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L.

Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, Wiltrout RH.

Cell Immunol. 2005 Jun;235(2):145-52. Epub 2005 Oct 6.

PMID:
16213477
25.

Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.

Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, Doja S, Jiang W, Subleski J, Shorts L, Haines D, Laubach VE, Wiltrout RH, Djurickovic D, Harris CC.

Cancer Res. 2004 Oct 1;64(19):6849-53.

26.

Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.

Welniak LA, Shorts L, Subleski J, Blazar BR, Wiltrout RH, Murphy WJ.

Biol Blood Marrow Transplant. 2004 Aug;10(8):534-9.

27.

Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells.

Zhang X, Rodriguez-Galán MC, Subleski JJ, Ortaldo JR, Hodge DL, Wang JM, Shimozato O, Reynolds DA, Young HA.

Blood. 2004 Nov 15;104(10):3276-84. Epub 2004 Jul 20.

PMID:
15265789
28.

Activation of cutaneous protein kinase C alpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways.

Cataisson C, Joseloff E, Murillas R, Wang A, Atwell C, Torgerson S, Gerdes M, Subleski J, Gao JL, Murphy PM, Wiltrout RH, Vinson C, Yuspa SH.

J Immunol. 2003 Sep 1;171(5):2703-13.

29.

Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.

Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH.

J Immunol. 2003 Mar 1;170(5):2727-33.

30.
31.

Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.

Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton JM, Wiltrout RH.

Cancer Res. 2001 Aug 15;61(16):6255-63.

32.

IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH.

J Clin Invest. 2001 Jul;108(1):51-62.

33.

Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).

Park JW, Gruys ME, McCormick K, Lee JK, Subleski J, Wigginton JM, Fenton RG, Wang JM, Wiltrout RH.

J Immunol. 2001 Mar 15;166(6):3763-70.

34.

IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation.

Geiselhart LA, Humphries CA, Gregorio TA, Mou S, Subleski J, Komschlies KL.

J Immunol. 2001 Mar 1;166(5):3019-27.

35.
36.

Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene.

Curiel RE, Lahesmaa R, Subleski J, Cippitelli M, Kirken RA, Young HA, Ghosh P.

Eur J Immunol. 1997 Aug;27(8):1982-7.

PMID:
9295035
37.

Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway.

Ghosh P, Sica A, Cippitelli M, Subleski J, Lahesmaa R, Young HA, Rice NR.

J Biol Chem. 1996 Mar 29;271(13):7700-4.

38.

Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.

Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC.

J Natl Cancer Inst. 1995 Oct 4;87(19):1478-83.

PMID:
7674335
39.

RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter.

Lai JH, Horvath G, Subleski J, Bruder J, Ghosh P, Tan TH.

Mol Cell Biol. 1995 Aug;15(8):4260-71.

40.

Characterization of a silencer regulatory element in the human interferon-gamma promoter.

Ye J, Ghosh P, Cippitelli M, Subleski J, Hardy KJ, Ortaldo JR, Young HA.

J Biol Chem. 1994 Oct 14;269(41):25728-34.

Supplemental Content

Loading ...
Support Center